Alvogen has just announced the appointment of Faysal Kalmoua as their new Executive Vice President of Portfolio. Kalmoua joins Alvogen with an impressive track record in the pharma industry. Originally a medicinal chemist, his many qualifications include a Masters Degree in Chemistry (M.Sc.) and a Global Executive MBA from Insead.
He started at Synthon, where he worked for more than fifteen years, first as a Project Manager for some key products and subsequently as Head of Business Development, Project Management and Portfolio Management. His main focus has been on "complex" generics, including first-to-file/ first-to-market opportunities and paths to differentiate from competitors.
In his new role at Alvogen, Faysal Kalmoua will be responsible for leading the company's portfolio, as the company continues to expand its pipeline and show dynamic global growth.
“I have every confidence that Faysal's invaluable experience in the pharmaceutical industry will be of great strategic value to the company,” Alvogen’s CEO and chairman Robert Wessman commented, “ his dynamic approach and impressive leadership skills make him the ideal man for this job and a true asset for our team.”
Faysal Kalmoua added:
„I am delighted to join a world class company like Alvogen, which has an impressive growth story and compelling strategy. I look forward to working closely with Alvogen's employees and shareholders and support Alvogen on its growth journey to become a top ten Global Generics player. “